- Home
- INSM
INSM
Insmed Incorporated
as 09-05-2025 4:00pm EST
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 26.0B | IPO Year: | 2000 |
| Target Price: | $142.38 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $146.84 | Next Earning Date: | 10-30-2025 |
| Revenue: | $398,105,000 | Revenue Growth: | 21.15% |
| Revenue Growth (this year): | 32.47% | Revenue Growth (next year): | 126.03% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Flammer Martina M.D. | INSM | Chief Medical Officer | Sep 2 '25 | Sell | $143.65 | 186,648 | $26,941,272.29 | 209,571 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Sep 2 '25 | Sell | $143.60 | 24,272 | $3,492,377.99 | 54,902 | |
| SHAROKY MELVIN MD | INSM | N/A | Aug 20 '25 | Sell | $129.50 | 10,000 | $1,295,000.00 | 274,516 | |
| Adsett Roger | INSM | Chief Operating Officer | Aug 19 '25 | Sell | $127.85 | 25,000 | $3,189,585.95 | 110,444 | |
| Lewis William | INSM | Chair and CEO | Aug 18 '25 | Sell | $128.61 | 6,865 | $881,470.20 | 233,924 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Aug 14 '25 | Sell | $127.48 | 10,000 | $1,273,363.44 | 79,764 | |
| SHAROKY MELVIN MD | INSM | N/A | Aug 12 '25 | Sell | $121.58 | 10,000 | $1,215,800.00 | 274,516 | |
| Bonstein Sara | INSM | Chief Financial Officer | Jun 23 '25 | Sell | $101.93 | 57,765 | $5,879,088.99 | 102,197 | |
| Lewis William | INSM | Chair and CEO | Jun 16 '25 | Sell | $100.00 | 135,009 | $13,553,743.64 | 233,924 | |
| Adsett Roger | INSM | Chief Operating Officer | Jun 16 '25 | Sell | $98.91 | 10,686 | $1,056,003.52 | 110,444 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MT Newswires
3 days ago
Insmed Insider Sold Shares Worth $26,941,272, According to a Recent SEC Filing
Pharmaceutical Technology
4 days ago
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
Zacks
5 days ago
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
Investor's Business Daily
6 days ago
Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It
Investor's Business Daily
6 days ago
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
PR Newswire
12 days ago
Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution
GlobeNewswire
14 days ago
Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.